41 results
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
disease and chronic autoimmune disorders.
In August, the company also presented data comprising the clinical package for the OTL-200 BLA in MLD
8-K
EX-99.2
ORTX
Orchard Therapeutics plc
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
initiated Apr. 2023 Pre-BLA meeting held with multi-disciplinary review team at the FDA to align on final BLA package, rolling BLA timeline and content … from members of the BLA review team Jan. 2023 Productive Type B meeting with the FDA to align on clinical package, including natural history, etc. BLA
8-K
EX-99.1
ar13nm 0g373h8nmqno
14 Nov 22
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
7:10am
8-K
EX-99.2
33rqn8j
10 Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
7:05am
8-K
EX-99.1
5822q0vl0msd mqfhv
10 Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
7:05am
8-K
EX-99.1
lq7i4
4 Aug 21
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
7:05am
8-K
EX-99.1
ta1mb5gw oamgehu
29 Jun 21
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
7:05am